Welcome to our dedicated page for Atossa Therapeutics SEC filings (Ticker: ATOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial timelines, secondary offerings, and evolving patent claims make Atossa Therapeutics filings anything but straightforward. Each 8-K can reveal a pivotal breast-cancer study update or a new equity raise that shifts dilution math overnight. Skimming hundreds of pages to locate these nuggets is a real hurdle for biotech investors.
Stock Titan removes that friction. Our AI reads every incoming document on EDGAR, then delivers plain-English highlights that show exactly where R&D spend changed, which trial cohort advanced, and how many shares management just registered. Whether you need an Atossa Therapeutics quarterly earnings report 10-Q filing breakdown or Atossa Therapeutics 8-K material events explained, the platform serves it in minutes, not hours.
Here鈥檚 what you can explore today:
- AG真人官方-time alerts for Atossa Therapeutics Form 4 insider transactions real-time鈥攌now when executives buy or sell.
- Concise AI notes that make an Atossa Therapeutics annual report 10-K simplified enough to read over coffee.
- Line-by-line Atossa Therapeutics earnings report filing analysis for quick trend checks.
- Instant answers to 鈥�Atossa Therapeutics proxy statement executive compensation鈥� or other board-level queries.
From 鈥�Atossa Therapeutics insider trading Form 4 transactions鈥� to 鈥�understanding Atossa Therapeutics SEC documents with AI,鈥� every disclosure is summarized, searchable, and actionable. Stop digging through PDFs; let our expert system surface the capital raises, patent wins, and trial results that move the stock.
Atossa Therapeutics reported widening losses as it advances clinical programs for its lead candidate, oral (Z)-endoxifen. For the six months ended June 30, 2025 the company recorded a $15.1 million net loss and used $13.2 million of cash in operations, compared with $11.9 million and $9.2 million a year earlier. Cash and cash equivalents totaled $57.9 million at June 30, 2025, with working capital of $55.7 million, and management expects this cash to fund operations for at least one year. Total operating expenses rose to $16.5 million for the six-month period driven by higher R&D spending on (Z)-endoxifen trials.
The company highlighted positive clinical signals: low-dose (Z)-endoxifen reduced mammographic breast density (1 mg: 17.3%, 2 mg: 23.5%, both p<0.01) and neoadjuvant and I-SPY 2 data showed tumor suppression and tolerability. Material items to monitor include pending PTAB proceedings challenging two patents (petitions filed by Intas), a non-cancellable clinical commitment of $7.9 million, and a Nasdaq notice requiring the company to regain a $1.00 bid compliance by August 20, 2025.
Atossa Therapeutics, Inc. reported on August 12, 2025 that it issued a press release announcing financial results for the quarter ended June 30, 2025 and providing a company update. The press release is attached as Exhibit 99.1 and the filing includes a cover page Interactive Data File as Exhibit 104. The Company states the information in Items 2.02 and 9.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or subject to certain Securities Act liabilities. This Current Report is signed by Heather Rees, Chief Financial Officer. No numerical financial metrics are included in the 8-K text provided here; consult Exhibit 99.1 for the detailed results and commentary.
FAQ
What is the current stock price of Atossa Therapeutics (ATOS)?
What is the market cap of Atossa Therapeutics (ATOS)?
